A5000578425- Chronic Lymphocytic Leukemia Research
- Ubiquitin and proteasome pathways
- Phagocytosis and Immune Regulation
- Lung Cancer Research Studies
- Glycosylation and Glycoproteins Research
- Immune Cell Function and Interaction
- Lymphoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Renal and related cancers
- Viral-associated cancers and disorders
- Immunotherapy and Immune Responses
- Immune cells in cancer
- Cancer Research and Treatments
- Cancer Mechanisms and Therapy
- RNA Interference and Gene Delivery
- Cancer-related gene regulation
- Chemokine receptors and signaling
- CAR-T cell therapy research
- Genomic variations and chromosomal abnormalities
- Histone Deacetylase Inhibitors Research
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Protein Degradation and Inhibitors
- Multiple Myeloma Research and Treatments
- Galectins and Cancer Biology
University of Cologne
2017-2023
University Hospital Bonn
2020-2022
Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases
2018-2020
University Hospital Cologne
2018
Abstract Deciphering the evolution of cancer cells under therapeutic pressure is a crucial step to understand mechanisms that lead treatment resistance. To this end, we analyzed whole-exome sequencing data eight chronic lymphocytic leukemia (CLL) patients developed resistance upon BCL2-inhibition by venetoclax. Here, report recurrent mutations in BTG1 (2 patients) and homozygous deletions affecting CDKN2A/B (3 during treatment, as well mutation BRAF high-level focal amplification CD274 (...
Abstract Small cell lung cancer (SCLC) represents the most aggressive pulmonary neoplasm and is often diagnosed at late stage with limited survival, despite combined chemotherapies. We show in an autochthonous mouse model of SCLC that anti-VEGF/anti-PD-L1–targeted therapy synergistically improves treatment outcome compared anti–PD-L1 anti-VEGF monotherapy. Mice treated alone relapsed after 3 weeks were associated a tumor-associated PD-1/TIM-3 double-positive exhausted T-cell phenotype. This...
Abstract T-cell prolymphocytic leukemia (T-PLL) is a rare and poor-prognostic mature malignancy. Here we integrated large-scale profiling data of alterations in gene expression, allelic copy number (CN), nucleotide sequences 111 well-characterized patients. Besides prominent signatures activation prevalent clonal variants, also identify novel hot-spots for CN variability, fusion molecules, alternative transcripts, progression-associated dynamics. The overall lesional spectrum T-PLL mainly...
T-cell prolymphocytic leukemia (T-PLL) is a poor prognostic disease with very limited options of efficient therapies. Most patients are refractory to chemotherapies and despite high response rates after alemtuzumab, virtually all relapse. Therefore, there an unmet medical need for novel therapies in T-PLL. As the chemokine receptor CCR7 molecule expressed wide range malignancies relevant many tumor processes, present study addressed biologic role this Furthermore, we elucidated mechanisms...
Natali Pfluga*, Paula Cramera, Sandra Robrechta, Jasmin Bahloa, Anne Westermanna, Anna-Maria Finka, Alexandra Schradera, Petra Mayera, Sebastian Oberbecka, Till Seilerb, Thorsten Zenzc, Jan Dürigd, Karl-Anton Kreuzera, Stephan Stilgenbauere, Barbara Eichhorsta, Michael Halleka**, Marco Herlinga* & Georg Hopfingerf*a Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, Deutsche CLL Studiengruppe (DCLLSG), Excellence Cluster Cellular Stress Response and Aging-Associated...
The generation and expansion of functionally competent NK cells in vitro is great interest for their application immunotherapy cancer. Since CD33 constitutes a promising target myeloid malignancies, expressing CD33-specific chimeric antigen receptor (CAR) were generated. Unexpectedly, we noted that CD33-CAR could not be efficiently expanded due to fratricide-like process which killed other had upregulated culture. This upregulation was dependent on the stimulation protocol encompassed up 50%...
Abstract T-cell prolymphocytic leukemia (T-PLL) is a chemotherapy-refractory malignancy with limited therapeutic options and poor prognosis. Current disease concepts implicate TCL1A oncogene-mediated enhanced receptor (TCR) signaling aberrant DNA repair as central perturbed pathways. We discovered that recurrent gains on chromosome 8q more frequently involve the argonaute RISC catalytic component 2 (AGO2) gene than adjacent MYC locus affected minimally amplified genomic region. AGO2 has been...
T-cell receptor (TCR) β repertoire analysis can distinguish monoclonal from polyclonal proliferations and crucially aid in the diagnosis of malignancies. TCR be assessed either by flow cytometry (FCM), or molecular genetic techniques. We compared results parallel analyses Vβ expression FCM TRB rearrangements DNA-based next-generation sequencing (NGS) 80 diagnostic peripheral blood samples patients with prolymphocytic leukemia (T-PLL) for (1) clonality (2) assessment dominant usage. FCM-based...
Abstract The pathogenesis of the rare and aggressive T-cell prolymphocytic leukemia (T-PLL) is poorly understood, which particularly applies to a mechanistic concept around its hallmark oncogene TCL1A. Existing data implicate TCL1A as catalytic enhancer oncogenic kinase AKT, central node in T-cell’s antigen receptor (TCR) signaling cascade, mediates proliferation differentiation. levels role TCR activation T-PLL’s are not known. To first clarify physiological subset T-PLL cells most...
<div>Abstract<p>Small cell lung cancer (SCLC) represents the most aggressive pulmonary neoplasm and is often diagnosed at late stage with limited survival, despite combined chemotherapies. We show in an autochthonous mouse model of SCLC that anti-VEGF/anti-PD-L1–targeted therapy synergistically improves treatment outcome compared anti–PD-L1 anti-VEGF monotherapy. Mice treated alone relapsed after 3 weeks were associated a tumor-associated PD-1/TIM-3 double-positive exhausted...
<div>Abstract<p>T-cell prolymphocytic leukemia (T-PLL) is a chemotherapy-refractory T-cell malignancy with limited therapeutic options and poor prognosis. Current disease concepts implicate TCL1A oncogene-mediated enhanced receptor (TCR) signaling aberrant DNA repair as central perturbed pathways. We discovered that recurrent gains on chromosome 8q more frequently involve the <i>argonaute RISC catalytic component 2 (AGO2)</i> gene than adjacent <i>MYC</i>...
Supplementary Data from Noncanonical Function of AGO2 Augments T-cell Receptor Signaling in Prolymphocytic Leukemia
Supplementary Figure from Noncanonical Function of AGO2 Augments T-cell Receptor Signaling in Prolymphocytic Leukemia
Supplementary Data from Noncanonical Function of AGO2 Augments T-cell Receptor Signaling in Prolymphocytic Leukemia